Figure 4.

Prognostic value of the lymphocyte-specific kinase metagene in subgroups of breast cancer patients. Samples of the combined dataset were stratified according to the highest quartile of expression of the lymphocyte-specific kinase (LCK) metagene. Kaplan–Meier analyses of disease-free survival were performed in different tumor subgroups according to estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and stem-cell like (SCL) status. (a) The LCK metagene had a highly significant prognostic value among ER-negative samples. This high prognostic value was observed in all ER-negative samples independently of (b) their expression of SCL markers or (c) their HER2 status. (d) In addition, a high prognostic value of LCK metagene expression was also found in ER-positive HER2-positive samples.